CYP17A1 rs743572: Variant Overview and Evidence

What each genotype means

Variant Details and Genomic Context

The single nucleotide polymorphism rs743572 is situated on chromosome 10 in the 5' untranslated promoter region of the CYP17A1 gene, frequently designated historically as the -34 T>C or c.-34T>C polymorphism. Because the human genome can be read on either DNA strand, reference databases such as dbSNP register the alleles as T and C on the gene transcript strand, corresponding to A and G on the genomic reference sequence. In earlier literature, the common T allele was frequently referred to as the A1 allele, while the variant C allele was termed the A2 allele. Being positioned within the regulatory promoter area rather than a protein-coding exon, rs743572 does not alter the amino acid sequence of the resulting enzyme. Instead, early molecular models hypothesized that the nucleotide change might create an additional transcription factor binding site, potentially altering the rate of gene transcription, enzyme abundance, and subsequent steroid hormone synthesis.

Biological Role of the CYP17A1 Enzyme

The CYP17A1 gene encodes cytochrome P450 family 17 subfamily A member 1, a key membrane-bound dual-function enzyme localized to the endoplasmic reticulum of steroidogenic tissues such as the adrenal glands and gonads. This enzyme catalyzes two consecutive chemical transformations essential for human endocrinology: 17-alpha-hydroxylase activity and 17,20-lyase activity. Through these enzymatic reactions, pregnenolone and progesterone are converted into precursors for glucocorticoids such as cortisol, as well as downstream androgens like dehydroepiandrosterone (DHEA), androstenedione, and testosterone, which can subsequently be aromatized into estrogens. Because CYP17A1 occupies a pivotal junction deciding whether cholesterol derivatives become mineralocorticoids, glucocorticoids, or sex steroids, subtle alterations in its expression could theoretically shift systemic endocrine balances. Rare, severe loss-of-function mutations in CYP17A1 are known to cause congenital adrenal hyperplasia, whereas common regulatory variations like rs743572 have been examined for subtle shifts in physiological steroidogenesis.

Current Scientific Evidence and Clinical Validity

Over the past several decades, rs743572 has been heavily investigated across candidate-gene studies and epidemiological meta-analyses, particularly regarding susceptibility to hormone-dependent conditions. Early candidate studies suggested that the variant C (A2) allele might boost circulating estrogen or testosterone levels, raising susceptibility to breast, prostate, endometrial, and ovarian cancers, as well as conditions like polycystic ovary syndrome (PCOS). In pharmacogenomics, researchers also evaluated its potential influence on response to endocrine therapies, such as aromatase inhibitors, and taxane-based chemotherapies. However, larger replication cohorts and genome-wide association studies (GWAS) have yielded conflicting or weak statistical associations. While recent meta-analyses continue to show modest statistical correlations with select cancers, other comprehensive studies report no reproducible effect on circulating steroid concentrations or overall prostate cancer risk. Overall, clinical consortia categorize the evidence for rs743572 as limited and non-definitive.

Population Distribution and Allele Patterns

Unlike rare pathogenic mutations, rs743572 is a very common polymorphism globally. The minor allele frequency typically spans between 0.38 and 0.45 across major international populations represented in global sequencing catalogs such as gnomAD. Due to these balanced frequencies, all three genotypes—homozygous reference, heterozygous, and homozygous alternative—are regularly observed in clinical and population cohorts. Frequencies can vary modestly among populations of European, African, East Asian, and South Asian ancestry, but the variant remains prevalent across virtually all studied demographic groups. Because the variant is so widespread and yet has mild or neutral biological consequences on its own, researchers emphasize that carrying one or two copies of the variant allele does not signify pathology and must not be interpreted as an isolated clinical indicator.

What Consumers and Patients Should Know

Finding your rs743572 genotype on a direct-to-consumer genetic test or recreational genotyping panel cannot predict whether you will develop cancer or experience an adverse medication outcome. Because the overall scientific evidence remains limited, inconsistent, and predominantly associative, standard clinical practice guidelines do not recommend modifying lifestyle, medical screenings, or drug choices based on this single variant. Pharmacological dosing or therapy decisions—such as the administration of aromatase inhibitors or chemotherapy—are guided by validated clinical biomarkers, organ function, tumor staging, and formal medical guidelines. Individuals with concerns regarding their family history of hormone-related cancers or personal medication efficacy should seek professional medical advice. Always discuss prescription medications and therapeutic options with your clinician or pharmacist rather than attempting to self-manage or alter dosing based on recreational genetic results.

Frequently asked questions

Sources & further reading

Related variants in CYP17A1